Brain Tumor Lab, Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Aging (Albany NY). 2020 May 25;12(10):9151-9172. doi: 10.18632/aging.103185.
Mesenchymal stromal/stem cells (MSCs) are promising carriers in cell-based therapies against central nervous system diseases, and have been evaluated in various clinical trials in recent years. However, bone marrow-derived MSCs (BMSCs) are reportedly involved in tumorigenesis initiated by glioma stem-like cells (GSCs). We therefore established three different orthotopic models of GSC-MSC interactions using dual-color fluorescence tracing. Cell sorting and micropipetting techniques were used to obtain highly proliferative MSC monoclones from each model, and these cells were identified as transformed MSC lines 1, 2 and 3. Nineteen miRNAs were upregulated and 24 miRNAs were downregulated in all three transformed MSC lines compared to normal BMSCs. Reduced miR-146a-5p expression in the transformed MSCs was associated with their proliferation, malignant transformation and overexpression of heterogeneous nuclear ribonucleoprotein D. These findings suggest that downregulation of miR-146a-5p leads to overexpression of its target gene, heterogeneous nuclear ribonucleoprotein D, thereby promoting malignant transformation of MSCs during interactions with GSCs. Given the risk that MSCs will undergo malignant transformation in the glioma microenvironment, targeted glioma therapies employing MSCs as therapeutic carriers should be considered cautiously.
间质/干细胞(MSCs)是细胞治疗中枢神经系统疾病的有前途的载体,近年来已在各种临床试验中进行了评估。然而,据报道骨髓来源的 MSCs(BMSCs)参与了由神经胶质瘤干细胞样细胞(GSCs)引发的肿瘤发生。因此,我们使用双色荧光示踪建立了三种不同的 GSC-MSC 相互作用的原位模型。通过细胞分选和微量移液技术,从每个模型中获得高增殖性 MSC 单克隆,这些细胞被鉴定为转化 MSC 系 1、2 和 3。与正常 BMSCs 相比,所有三种转化 MSC 系中都有 19 个 miRNA 上调和 24 个 miRNA 下调。转化 MSC 中 miR-146a-5p 的表达减少与它们的增殖、恶性转化和异质核核糖核蛋白 D 的过表达有关。这些发现表明,miR-146a-5p 的下调导致其靶基因异质核核糖核蛋白 D 的过表达,从而促进了 MSCs 在与 GSCs 相互作用过程中的恶性转化。鉴于 MSCs 在神经胶质瘤微环境中可能发生恶性转化的风险,应谨慎考虑将 MSCs 作为治疗载体的靶向神经胶质瘤治疗。